Biotek-snakken — Marts 2023
-
Xbrane Biopharma AB: BioStock: Xbrane's CEO on the launch of Ximluci in Europe https://www.biostock.se/en/2023/03/xbranes-ceo-on-the-launch-of-ximluci-in-europe/
-
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients https://investors.evaxion-biotech.com/news-releases/news-release-details/evaxion-presents-new-source-ai-derived-immunotherapeutic-targets
-
Pharma og biotek - opdatering fra debat og chat uge 12 Ambu ' Novo Nordisk ' Bavarian Nordic ' Zealand Pharma
Helge Larsen gennemgår det sidste nye om virksomhederne inden for pharma og biotek ud fra den kvalificerede debat og chat på ProInvestor. https://www.proinvestor.com/boards/111628
-
BioNTech årsregnskab https://investors.biontech.de/node/14871/pdf 243 mio aktier kurs 113 €, MCAP 27.5 mia. Cash 13,9 mia
-
Er der nogen her der følger Brain+? Det er en sørgelig kursudvikling på det sidste. Nogen høvler aktier ud hver eneste dag
-
Brain+, sikke en klassiker, ny emission til kurs 1, nogen vidste noget
-
Saniona......herligt at Tesofensine endelig er blevet godkendt i Mexico, så Saniona kan begynde at få royalities langt om længe. Nu venter Argentina som det næste marked med Tesofensine, samt forhåbelig en partner til deres store guldæg, Tesomet. Er ikke i tvivl om, at Saniona kan mange dobles fra det nuværende niveau.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind